{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:11:25Z","timestamp":1790143885791,"version":"4.0.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n Parkinson\u2019s disease (PD) has traditionally been conceptualized as a neurodegenerative disorder centered within the central nervous system. However, growing evidence suggests that gastrointestinal dysfunction, intestinal permeability abnormalities, and gut microbiome dysbiosis may contribute to disease initiation and progression in a subset of patients. While several studies have characterized microbial alterations in PD, the integration of dysbiosis with intestinal barrier dysfunction and emerging phenotype-oriented models remains incompletely synthesized.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A systematic review and meta-analysis was conducted according to PRISMA 2020 guidelines. PubMed, Embase, Scopus, Web of Science, and Cochrane Library databases were searched from inception to January 2025 for studies evaluating gut microbiota composition and\/or intestinal permeability markers in Parkinson\u2019s disease. Random-effects meta-analysis was performed using standardized mean differences (SMDs) with subgroup and sensitivity analyses exploring geographic variation, sequencing methodology, disease duration, and phenotype-specific findings.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Thirty-four studies were identified; one (an experimental fecal-microbiota-transfer study in mice) was reclassified as preclinical mechanistic evidence rather than a primary human dataset. The remaining 33 human studies comprised 1,588 PD patients and 1,449 healthy controls. Consistent microbial alterations were identified across studies, characterized by depletion of short-chain fatty acid-producing taxa including\n Prevotella<\/jats:italic>\n ceae,\n Faecalibacterium<\/jats:italic>\n , and Lachnospiraceae, alongside enrichment of\n Akkermansia<\/jats:italic>\n , Bifidobacteriaceae, and Christensenellaceae. Elevated fecal calprotectin and zonulin levels suggested concomitant low-grade intestinal inflammation and impaired epithelial barrier integrity. In limited phenotype-stratified subgroup analyses, gut-first PD phenotypes showed potentially more pronounced dysbiosis patterns than brain-first phenotypes; this preliminary observation is based on very few phenotype-stratified studies and requires validation in larger, prospective cohorts. Functional interpretation of the included literature suggested potential alterations in butyrate metabolism, mucosal barrier maintenance, inflammatory signaling, and microbial-host immune interactions.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Parkinson\u2019s disease is associated with reproducible alterations in gut microbial composition together with evidence of intestinal barrier dysfunction. Although causality cannot be established from predominantly observational studies, the findings support a biologically plausible role for gut-related mechanisms in disease pathophysiology, with a preliminary signal for more pronounced involvement in gut-first PD phenotypes that remains to be confirmed. Future longitudinal and mechanistic studies integrating microbiome, metabolomic, and permeability data are required to clarify therapeutic and biomarker implications.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD420251078511<\/jats:ext-link>\n , CRD420251078511.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1909087","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:55:21Z","timestamp":1790142921000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gut\u2013brain axis dysfunction in Parkinson\u2019s disease: a meta-analysis of microbiome dysbiosis and intestinal barrier markers"],"prefix":"10.3389","volume":"13","author":[{"given":"Pulkit","family":"Mehrotra","sequence":"first","affiliation":[{"name":"Sri Ramachandra Medical College","place":["Porur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vengadakrishnan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sri Ramachandra Medical College","place":["Porur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Lucknow, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhasis","family":"Dan","sequence":"additional","affiliation":[{"name":"Independent Researcher","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/cns.13990","article-title":"Gut bacterial profiles in Parkinson's disease: a systematic review","volume":"29","author":"Li","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00415-025-13545-8","article-title":"The role of the gut microbiome in the progression of Parkinson's disease: a systematic review of patient cohorts","volume":"273","author":"Peters","year":"2025","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e28032","DOI":"10.1371\/journal.pone.0028032","article-title":"Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson disease","volume":"6","author":"Forsyth","year":"2011","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"103092","DOI":"10.1016\/j.redox.2024.103092","article-title":"Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS\/RNS: relevance to Parkinson's disease and therapeutic implications","volume":"71","author":"Kalyanaraman","year":"2024","journal-title":"Redox Biol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","article-title":"Gut microbiota are related to Parkinson's disease and clinical phenotype","volume":"30","author":"Scheperjans","year":"2015","journal-title":"Mov Disord"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson's disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"106655","DOI":"10.1016\/j.nbd.2024.106655","article-title":"Difference in gut microbial dysbiotic patterns between body-first and brain-first Parkinson's disease","volume":"201","author":"Park","year":"2024","journal-title":"Neurobiol Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1111\/ene.15671","article-title":"Gut microbiota dysbiosis in Parkinson disease: a systematic review and pooled analysis","volume":"30","author":"Bardenhorst","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/mds.28119","article-title":"Meta-analysis of gut dysbiosis in Parkinson's disease","volume":"35","author":"Nishiwaki","year":"2020","journal-title":"Mov Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"636545","DOI":"10.3389\/fnagi.2021.636545","article-title":"The Association Between the Gut Microbiota and Parkinson\u2019s Disease, a Meta-Analysis","volume":"13","author":"Shen","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"fcab085","DOI":"10.1093\/braincomms\/fcab113","article-title":"Gut microbiome \u03b1-diversity is not a marker of Parkinson\u2019s disease and multiple sclerosis","volume":"3","author":"Plassais","year":"2021","journal-title":"Brain Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fnins.2019.00992","article-title":"Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson's disease","volume":"13","author":"Budrewicz","year":"2019","journal-title":"Front Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"689723","DOI":"10.3389\/fnins.2021.689723","article-title":"Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson's disease","volume":"15","author":"Dumitrescu","year":"2021","journal-title":"Front Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13024-024-00766-0","article-title":"Gut-first Parkinson's disease is encoded by gut dysbiome","volume":"19","author":"Munoz-Pinto","year":"2024","journal-title":"Mol Neurodegener"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"112444","DOI":"10.1016\/j.exger.2024.112444","article-title":"Association between increased and decreased gut microbiota abundance and Parkinson's disease: a systematic review and subgroup meta-analysis","volume":"191","author":"Bai","year":"2024","journal-title":"Exp Gerontol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","article-title":"Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls","volume":"32","author":"Unger","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1007654","DOI":"10.3389\/fphar.2022.1007654","article-title":"Efficacy and safety of probiotics in Parkinson's constipation: a systematic review and meta-analysis","volume":"13","author":"Xie","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41467-023-36497-x","article-title":"An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants","volume":"14","author":"Hall","year":"2023","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1104759","DOI":"10.3389\/fneur.2023.1104759","article-title":"Fecal microbiota transplantation in Parkinson's disease\u2014a randomized repeat-dose, placebo-controlled clinical pilot study","volume":"14","author":"DuPont","year":"2023","journal-title":"Front Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"106791","DOI":"10.1016\/j.clineuro.2021.106791","article-title":"Fecal microbiota transplant as a potential treatment for Parkinson's disease \u2014 a case series","volume":"207","author":"Segal","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/brain\/awaa201","article-title":"Gut metagenomics-derived genes as potential biomarkers of Parkinson\u2019s disease","volume":"143","author":"Qian","year":"2020","journal-title":"Brain"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2018.02.022","article-title":"Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease","volume":"50","author":"Schwiertz","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson\u2019s Disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","article-title":"Colonic inflammation in Parkinson\u2019s disease","volume":"50","author":"Devos","year":"2013","journal-title":"Neurobiol Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1909087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:55:22Z","timestamp":1790142922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1909087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":27,"alternative-id":["10.3389\/fmed.2026.1909087"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1909087","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1909087"}}